- Mannheimia haemolytica serotype A1, to reduce infection, mortality, clinical signs, lung lesions and bacterial invasion of the lung caused by serotypes A1 and A6.

Cross-reactive immunity to the A6 serotype of Mannheimia haemolytica has been demonstrated in a challenge experiment under laboratory conditions after primary course of vaccination.

Approximately two weeks after completion of the basic immunisation programme, the humoral immune response against Bovine Respiratory Syncytial virus and Parainfluenza-3 virus is at its highest level. The duration of protective immunity has not been established in challenge experiments.

Onset of immunity: 2 weeks.

Duration of immunity: has not been established.

Dose to be administered and administration route

Method of administration:

Subcutaneous use. Injection into the side of the neck.

Dose: 5 ml.

Basic immunisation:

Animals from approximately 2 weeks of age should receive two vaccinations separated by an interval of approximately 4 weeks.

Booster doses:

If booster doses are required, a single dose should be given approximately 2 weeks before each risk period (e.g. transport, introduction into a herd, change of housing).

The vaccine must be shaken well before use.

For vaccine administration, needles of 1.5 to 2.0 mm diameter and 10 to 18 mm long are recommended. The vaccine should be brought to room temperature prior to use and injected quickly.

Adverse reactions

Cattle:

Common

(1 to 10 animals / 100 animals treated):

Injection site swelling¹.

Elevated temperature², reluctant to move.

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Hypersensitivity reaction³.

¹ In extreme cases narrow swellings up to 10 cm long. Typically, these swellings completely disappear or reduce in size to a negligible small lump within 2 to 3 weeks after vaccination, though in individual animals very small reactions can be found for up to 3 months.

² Slight and lasting a maximum of 3 days after vaccination.

³ May be fatal.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.